

# Should children be vaccinated against COVID-19?

Petra Zimmermann <sup>1,2,3</sup> Laure F Pittet <sup>3,4,5</sup> Adam Finn <sup>6,7</sup>  
Andrew J Pollard <sup>8,9</sup> Nigel Curtis <sup>3,4,10</sup>

<sup>1</sup>Faculty of Science and Medicine, University of Fribourg, Fribourg, Switzerland

<sup>2</sup>Department of Paediatrics, Fribourg Hospital HFR, Fribourg, Switzerland

<sup>3</sup>Infectious Diseases Research Group, Murdoch Children's Research Institute, Parkville, Victoria, Australia

<sup>4</sup>Department of Paediatrics, The University of Melbourne, Parkville, Victoria, Australia

<sup>5</sup>Pediatric Infectious Diseases Unit, Geneva University Hospitals and Faculty of Medicine, Geneva, Switzerland

<sup>6</sup>Bristol Vaccine Centre, School of Clinical Sciences and School of Cellular & Molecular Medicine, University of Bristol, Bristol, UK

<sup>7</sup>Bristol Royal Hospital for Children, University Hospitals Bristol NHS Foundation Trust, Bristol, UK

<sup>8</sup>Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK

<sup>9</sup>NIHR Oxford Biomedical Research Centre, Oxford, UK

<sup>10</sup>Infectious Diseases Unit, The Royal Children's Hospital Melbourne, Parkville, Victoria, Australia

## Correspondence to

Dr Petra Zimmermann, Faculty of Science and Medicine, University of Fribourg, Fribourg 1700, Switzerland; [petra.zimmermann@unifr.ch](mailto:petra.zimmermann@unifr.ch)

Received 18 August 2021  
Accepted 13 October 2021  
Published Online First  
3 November 2021



© Author(s) (or their employer(s)) 2022. No commercial re-use. See rights and permissions. Published by BMJ.

**To cite:** Zimmermann P, Pittet LF, Finn A, et al. *Arch Dis Child* 2022;**107**:e1.

## ABSTRACT

Whether all children under 12 years of age should be vaccinated against COVID-19 remains an ongoing debate. The relatively low risk posed by acute COVID-19 in children, and uncertainty about the relative harms from vaccination and disease mean that the balance of risk and benefit of vaccination in this age group is more complex. One of the key arguments for vaccinating healthy children is to protect them from long-term consequences. Other considerations include population-level factors, such as reducing community transmission, vaccine supply, cost, and the avoidance of quarantine, school closures and other lockdown measures. The emergence of new variants of concern necessitates continual re-evaluation of the risks and benefits. In this review, we do not argue for or against vaccinating children against COVID-19 but rather outline the points to consider and highlight the complexity of policy decisions on COVID-19 vaccination in this age group.

## INTRODUCTION

Whether all children should be offered vaccination against SARS-CoV-2 has been controversial in children aged 12–15 years old, and remains so for those under 12 years of age, partly because the balance of risk and benefit in this age group is more complex (see [figure 1](#)).

The risk of severe acute COVID-19 in healthy children infected with SARS-CoV-2 is much lower than in adults.<sup>1–10</sup> Two longer term consequences of SARS-CoV-2 infection might therefore be more of a concern in this age group. The first is ‘paediatric inflammatory multisystem syndrome-temporally associated with SARS-CoV-2 (PIMS-TS)’, also known as ‘multisystem inflammatory syndrome in children’, an immune-mediated disease that occurs in a small proportion of children 2–6 weeks after being infected with SARS-CoV-2.<sup>11–20</sup> The second is long COVID-19, the persistence of symptoms following SARS-CoV-2 infection, a heterogeneous group of conditions.<sup>21</sup>

Aside from potential long-term consequences, other considerations in deciding on COVID-19 vaccine policy for children include safety (both common reactions and rare serious side effects), population-level factors, such as reducing community transmission, vaccine supply, cost of vaccination, the avoidance of quarantine, school closures and other lockdown measures, and the potential impact on routine immunisation programmes.

In this review, we do not argue for or against vaccinating children against COVID-19 but rather outline the points to consider to highlight the

## What is already known on this topic?

- ▶ COVID-19 is generally asymptomatic or mild in children, but can be more severe in those with certain comorbidities.
- ▶ There is no consensus on whether all healthy children less than 12 years of age should be vaccinated against COVID-19.
- ▶ Data from COVID-19 vaccine use in this age group will become available in the near future.


## What this study adds?

- ▶ The balance of risks and benefits of COVID-19 vaccination in children is more complex than in adults as the relative harms from vaccination and disease are less well established in this age group.
- ▶ One of the key arguments for vaccinating children less than 12 years of age, apart from reducing acute illness, is to protect them from long-term consequences of COVID-19; other considerations include population-level factors.
- ▶ The risks and benefits need continual re-evaluation with the emergence of new variants of concern, and new data on effectiveness and adverse effects.

complexity of policy decisions on COVID-19 vaccination in this age group.

## Benefits and risks of vaccinating children against COVID-19

The main question for implementing any vaccine is ‘do the benefits of the vaccine in preventing the harms of the disease outweigh any known or potential risks associated with vaccination?’ To date, two COVID-19 vaccines have been shown to be effective in children aged 12–17 years, and have been authorised for emergency use and subsequently recommended for this age group in many countries.<sup>22–26</sup> Both vaccines are currently being evaluated in children aged 6 months–12 years and it is likely that emergency authorisation will be sought in this age group soon. Nevertheless, COVID-19 vaccine trials in adolescents so far include less than 4000 participants and appropriately focus on efficacy, immunogenicity and rates of common reactions.<sup>25 26</sup> A phase 2/3 trial in children 5–12 years of age recently reported that a messenger RNA (mRNA) vaccine was safe, well tolerated and induced robust neutralising antibodies.<sup>27</sup> Results from the same trial in children under 5 years of age are expected by the



**Figure 1** Summary of benefits and risks of vaccinating children against COVID-19. PIMS-TS, paediatric inflammatory multisystem syndrome-temporally associated with SARS-CoV-2.

end of 2021. Rare adverse effects are difficult to detect with such sample sizes, and are often seen only after large-scale use. Outside clinical trials, millions of adolescents between 12 and 18 years of age have been vaccinated, including 13 million in the USA.<sup>28</sup> Arguments for and against vaccinating children against COVID-19 are summarised in [table 1](#).

### Potential benefits of vaccinating children

#### Protection against COVID-19

COVID-19 is generally a mild disease in children with less than 2% of symptomatic children requiring hospital admission.<sup>1–10</sup> The rate of intensive care admission of hospitalised children ranges between 2% and 13%.<sup>1 7 8 29 30</sup> Higher rates (10%–25%,<sup>31 32</sup> up to 33% in some studies<sup>33 34</sup>) are reported from the USA. However, these numbers often include children who are hospitalised with COVID-19 and not because of COVID-19, and therefore overestimate the severity. In children and adolescents, the risk of death from SARS-CoV-2 infection is 0.005%,<sup>35</sup> and in those who are hospitalised with COVID-19 it is 0%–0.7%.<sup>1 7 8 29 30 33 34</sup> However, again, these numbers often include children who died with a SARS-CoV-2 infection and not because of it (a recent population-based study showed that only 41% of child deaths reported from SARS-CoV-2 infections were from COVID-19).<sup>35</sup> Therefore, the prevention of SARS-CoV-2 infection is not as strong an argument for vaccinating all healthy children as it is for adults. Nevertheless, this might change if new variants emerge which cause more severe disease in otherwise healthy children.

There are insufficient data to estimate the risk of myocarditis in children and adolescents with COVID-19, although one report from the USA suggested a risk of 876 cases per million.<sup>36</sup> Another study reported an adjusted risk ratio for myocarditis from patients with COVID-19 compared with patients without COVID-19 of 36.8 in children less than 16 years of age and 7.4 in adolescents 16–24 years of age.<sup>37</sup> A third study reported an 8.2-fold increase in myocarditis admissions during the pandemic, but no cases among the 1371 children and adolescents less than 18 years of age.<sup>38</sup> Information on the long-term outcome of

myocarditis resulting from SARS-CoV-2 infection (e.g., progression to fibrosis) is currently lacking.

In the USA, with the emergence of the more transmissible Delta variant, a recent rise in infections in children has led to overcrowded hospital and intensive care units.<sup>39</sup> For hospitalised children, intensive care admission and mortality rates are currently stable at 23% and 0.4%<sup>29</sup>–1.8%,<sup>30</sup> respectively. Of note, this has occurred in settings with low vaccine coverage in adults and suboptimal preventive measures in place. There are no reports indicating an increase in the severity of COVID-19 in children since the Delta variant has become dominant.

At this time, COVID-19 vaccines only have ‘emergency use authorisation’ in children between 12 and 16 years of age, which is for interventions that address a serious or life-threatening condition. It has been argued that, unless children are at high risk of severe COVID-19 because of an underlying condition, it is unclear whether the benefits to the individual outweigh the risks in this age group, and approval through the standard regulatory process should be awaited.<sup>40</sup>

There are good reasons to consider offering vaccination to children and adolescents at higher risk of being hospitalised or becoming severely unwell from a SARS-CoV-2 infection, as, in their case, the risk of harm from vaccination is estimated to be lower than the risk of harm from COVID-19. This includes children with neurodisabilities, Down’s syndrome, immunodeficiencies, malignancies, some cardiac, respiratory and renal diseases, obesity and poorly controlled diabetes.<sup>41</sup>

The low risk of hospitalisation and death from COVID-19 might not be a good argument against vaccinating against this disease as the risk is similar or even higher than that for other diseases for which vaccines are routinely given, such as varicella, rubella, hepatitis A and influenza.<sup>42</sup> In addition, if a high proportion of children are infected, even a very low rate of severe illness might translate to a high absolute number of cases. Moreover, in low/middle-income countries (LMICs), the impact of COVID-19 in children may be greater due to comorbidities that impact immunity, including diarrhoea, dengue fever, tuberculosis, malnutrition, stunting and anaemia.<sup>33</sup> Similarly, in high-income

**Table 1** Arguments for and against vaccinating children against COVID-19

	Arguments for COVID-19 vaccination	Arguments against COVID-19 vaccination
<b>Benefits of vaccinating children</b>		
(1) Protection against COVID-19	<ul style="list-style-type: none"> <li>▶ Good justification if risk of SARS-CoV-2 infection is high</li> <li>▶ Risk of harm from vaccination lower than risk of harm from COVID-19<sup>91</sup></li> <li>▶ Clear benefit for children with risk factors for severe COVID-19<sup>41</sup></li> <li>▶ Risk of hospitalisation and death from COVID-19 is commensurate with or higher than other diseases in routine immunisation programme<sup>42</sup></li> <li>▶ Higher disease burden of COVID-19 in children in LMICs with comorbidities that impact immunity<sup>33</sup></li> <li>▶ Higher immunogenicity of mRNA vaccines in children might mean one or lower dose sufficient<sup>25</sup></li> <li>▶ Adolescents have a higher frequency of infection and disease burden than younger children</li> </ul>	<ul style="list-style-type: none"> <li>▶ Children are less likely to get infected after a SARS-CoV-2 exposure<sup>77 111–114</sup></li> <li>▶ Most children have asymptomatic or mild COVID-19<sup>1–8</sup></li> <li>▶ A large proportion of children might already be immune to SARS-CoV-2 in many regions of the world</li> <li>▶ Risk of COVID-19 in children might be less if large proportion of adult population is vaccinated</li> </ul>
(2) Protection against severe COVID-19	<ul style="list-style-type: none"> <li>▶ Risk of severe COVID-19 in children with underlying diseases is not negligible<sup>1–8</sup></li> <li>▶ Risk of severe COVID-19 in healthy children might be higher with SARS-CoV-2 current or future variants of concern</li> </ul>	<ul style="list-style-type: none"> <li>▶ Risk of severe COVID-19 in healthy children is low<sup>1–8</sup></li> <li>▶ At-risk children could be protected by targeted rather than universal vaccination</li> </ul>
(3) Protection against PIMS-TS	<ul style="list-style-type: none"> <li>▶ No long-term data on children with PIMS-TS; if sequelae are important, the risk–benefit of COVID-19 vaccination might change</li> </ul>	<ul style="list-style-type: none"> <li>▶ No data yet on whether vaccination prevents PIMS-TS</li> <li>▶ Risk of PIMS-TS is low, and children mainly recover without sequelae<sup>11–19</sup></li> <li>▶ COVID-19 vaccination might increase risk of PIMS-TS (no evidence to date)</li> </ul>
(4) Protection against long COVID-19	<ul style="list-style-type: none"> <li>▶ Long COVID-19 can occur even after mild or asymptomatic infection<sup>55 57 58 61 65 66</sup></li> <li>▶ Not well studied yet; could affect a large number of children</li> </ul>	<ul style="list-style-type: none"> <li>▶ The incidence of long COVID-19 is still to be accurately determined<sup>21</sup></li> <li>▶ Difficult to separate infection-associated from pandemic-associated symptoms<sup>55 61 65</sup></li> </ul>
(5) Prevention of community transmission	<ul style="list-style-type: none"> <li>▶ Children, even young children, can transmit SARS-CoV-2<sup>115</sup></li> <li>▶ Prevention of transmission to other children and older age groups</li> <li>▶ Prevention of transmission to high-risk household members</li> <li>▶ Herd immunity likely inachievable without vaccinating children and adolescents</li> <li>▶ Reduction in the risk of new VOC emerging</li> <li>▶ Risk of transmission might be changing with emergence of new VOC (eg, Delta)</li> <li>▶ Potential considerable indirect benefit (eg, schools remaining open) to children even if no direct benefit (see (6))</li> <li>▶ ‘No one is safe until we are all safe’</li> </ul>	<ul style="list-style-type: none"> <li>▶ No data yet on whether vaccination prevents transmission in children</li> <li>▶ Transmission in educational settings is rare and index cases are often adults<sup>78–81</sup></li> <li>▶ Index cases in households much more likely to be a parent or adolescent<sup>6</sup></li> <li>▶ Community transmission will decrease if sufficient adults are vaccinated<sup>69</sup></li> <li>▶ Subjecting children to potential risk of vaccine adverse effects to drive indirect effects with little or no direct benefit might be ethically questionable</li> <li>▶ Effect of vaccination on transmission might decrease with waning immunity and emergence of VOC</li> <li>▶ Primary infection at young age when the disease is mild combined with boosting exposure from ongoing transmission at older age might be better strategy<sup>90</sup></li> </ul>
(6) Avoidance of indirect harms, including quarantine, school closure and other harms of lockdowns	<ul style="list-style-type: none"> <li>▶ Transmission in school can contribute to the circulation of SARS-CoV-2<sup>77</sup></li> <li>▶ Lockdowns and school closures have a major impact on physical and mental health of children<sup>116</sup></li> <li>▶ Vaccinated children might be exempt from quarantine</li> <li>▶ COVID-19 vaccination might become a requirement for international travel</li> </ul>	<ul style="list-style-type: none"> <li>▶ Might not be sufficient to prevent school closures and lockdowns (especially if a large proportion of adults are not vaccinated)</li> <li>▶ Might not be necessary to prevent school closures and lockdowns, especially if adult staff are all immunised</li> </ul>

Continued

Table 1 Continued

	Arguments for COVID-19 vaccination	Arguments against COVID-19 vaccination
<b>Risks of vaccinating children</b>		
(1) Risk of adverse effects	<ul style="list-style-type: none"> <li>▶ Myocarditis after mRNA vaccines is transient and usually without sequelae<sup>91</sup></li> <li>▶ No reports of thrombosis after viral vector vaccines in children and adolescents to date<sup>99</sup></li> <li>▶ No reports of PIMS-TS after vaccination to date</li> </ul>	<ul style="list-style-type: none"> <li>▶ Myocarditis after mRNA vaccines including need for intensive care<sup>91–98 117</sup></li> <li>▶ Potential risk of thrombosis after viral vector vaccines</li> <li>▶ Potential trigger for PIMS-TS (no evidence to date)</li> </ul>
(2) Long-term safety	<ul style="list-style-type: none"> <li>▶ Adverse effects of vaccines usually occur early</li> </ul>	<ul style="list-style-type: none"> <li>▶ Long-term safety in children, including following myocarditis, unknown</li> <li>▶ If concerns arise, this might lead to decrease in vaccine confidence and vaccine uptake, including against other diseases<sup>102</sup></li> <li>▶ No studies to date have evaluated co-administration with other vaccines</li> </ul>
(3) Vaccine supply	<ul style="list-style-type: none"> <li>▶ One dose or a reduced dose might be sufficient in children</li> </ul>	<ul style="list-style-type: none"> <li>▶ Current limited vaccine supply should be prioritised for people at high risk of severe disease and death</li> <li>▶ Vaccine supply might be better used for adults in LMICs where &lt;5% of population have been vaccinated<sup>103</sup></li> </ul>
(4) Cost	<ul style="list-style-type: none"> <li>▶ Greater herd immunity likely better for returning to pre-pandemic economic stability</li> </ul>	<ul style="list-style-type: none"> <li>▶ Likely higher cost–benefit ratio in children</li> </ul>
(5) Other immunisation programmes	<ul style="list-style-type: none"> <li>▶ Could be combined with the administration of other routine vaccines</li> </ul>	<ul style="list-style-type: none"> <li>▶ Implementation of universal COVID-19 vaccination programme in children could cause delays in the routine immunisation programmes by using up existing delivery resources and personnel</li> </ul>

LMICs, low/middle-income countries; mRNA, messenger RNA; PIMS-TS, paediatric inflammatory multisystem syndrome-temporally associated with SARS-CoV-2.

countries, children from deprived and ethnic minority groups are more frequently infected with SARS-CoV-2, which might be due to a greater likelihood of living with unvaccinated adults or in multigenerational and overcrowded households.<sup>43 44</sup> These children have also been reported to have more severe COVID-19 and to more frequently suffer from PIMS-TS.<sup>45–47</sup>

### Protection against PIMS-TS

The risk of PIMS-TS is low, affecting less than 0.1% of SARS-CoV-2-infected children. Although up to 70% of children with PIMS-TS are admitted to intensive care units,<sup>48 49</sup> almost all patients recover without sequelae.<sup>11–20 48 50 51</sup> Between 79% and 100% of abnormal cardiac findings are reported to resolve within 14–30 days after hospital discharge.<sup>48 52 53</sup> Six months after discharge, 96% of children have a normal echocardiography, and renal, haematological, otolaryngological and neurological abnormalities have largely resolved.<sup>45</sup> However, the long-term consequences of PIMS-TS remain uncertain and the death rate from PIMS-TS is estimated to be 1%–2%.<sup>48 49</sup> There is no evidence to date on whether vaccination protects against PIMS-TS: although by protecting against SARS-CoV-2 infection it may well also protect against post-infectious sequelae; data are needed to confirm this. Since the pathogenesis of PIMS-TS remains unclear, there is also a theoretical risk that antibodies induced by COVID-19 vaccination could cause PIMS-TS, though there is no evidence of this to date.

### Protection against long COVID-19

While vaccination prevents infection with SARS-CoV-2 to a degree and thus, presumably, persistent symptoms following the infection, more data are needed to determine accurately the incidence of long COVID-19 in children.<sup>21</sup> Studies to date report a prevalence ranging from 1.2% to 66%.<sup>54–64</sup> However, most of these studies have substantial limitations, including a lack of a clear case definition, the absence of a control group without infection, inclusion of children without laboratory-confirmed SARS-CoV-2 infection, follow-up at arbitrary time points and high non-responder bias.<sup>54–63 65–68</sup> Of the five studies to date that have included controls,<sup>55 59 61 65</sup> two did not find a difference in the prevalence of persistent symptoms between infected and uninfected children.<sup>61 65</sup> This highlights the difficulty of separating COVID-19-related symptoms from those attributable to other factors associated with the pandemic, such as lockdowns and school closures. The three that did find a difference had significant limitations, including potential selection bias due to a high non-responder rate, that could lead to an overestimate of the risk of long COVID-19.<sup>55 59</sup>

### Prevention of community transmission

Another advantage of vaccinating children is helping decrease transmission and thus reducing severe cases in adults and the risk of new virus variants emerging. As well as reducing disease, COVID-19 vaccines also reduce infection. Initial studies reported that vaccinated individuals who become infected are

less likely to transmit the virus due to decreased viral load and duration of virus shedding<sup>69 70</sup> and as a consequence, transmission from vaccinated individual to household contacts is significantly lower<sup>71</sup> (by 50% in one study<sup>69</sup>). However, more recent studies done since the Delta variant became dominant show similar viral loads in vaccinated and unvaccinated individuals.<sup>72–75</sup>

Children, including young children, can transmit SARS-CoV-2.<sup>76</sup> Nonetheless, even though transmission in schools can contribute to the circulation of SARS-CoV-2,<sup>77</sup> the rate of transmission in educational settings is low and index cases are often adults.<sup>78–81</sup> The risk of infection in schools correlates strongly with local community infection rates, which can be reduced by vaccinating older age groups. Nevertheless, the risk of transmission in different age groups and settings might change with the emergence of new virus variants of concern. For the Delta variant, it has been suggested that infected fully vaccinated individuals are as likely to transmit SARS-CoV-2 as infected unvaccinated individuals, although for shorter duration.<sup>82 83</sup> However, recent data from Australia reported a low risk of transmission in educational settings with protection measurements in place, even with the Delta variant (the transmission rate from adults to children was 8%, from children to adults 1.3% and from children to other children 1.8%).<sup>84</sup>

Earlier in the pandemic, it was reported that index cases in households were more likely to be a parent or adolescent than a young child.<sup>6 85–87</sup> However, one study suggests that children and adolescents are more likely to infect others.<sup>88</sup> Another study reported that household transmission was more common from children aged 0–3 years than from children aged 14–17 years.<sup>89</sup> However, this might change with the Delta or other new variants. In a population with low numbers of vaccinated adults, infected children transmitted the Delta variant to 70% of households (in 57% of households all members became infected).<sup>84</sup> Nevertheless, once a large proportion of the adult population is vaccinated, preventing transmission to them from unvaccinated children becomes less important. There is a stronger argument for vaccinating children and adolescents who live with immunosuppressed or other high-risk household members, not only for the protection of the latter but also to benefit the mental health of the former. Also, in LMICs children under 12 years of age form a larger proportion of the population and might therefore have a larger role in transmission.

Another consideration is that, once SARS-CoV-2 becomes endemic, primary SARS-CoV-2 infection in early childhood, when COVID-19 is mild, with subsequent boosting from ongoing exposure at older ages, may bring about population immunity, as seen with common circulating coronaviruses, more effectively than mass immunisation.<sup>90</sup>

#### Avoidance of indirect (population-level) harms

Vaccinating children and adolescents might help reduce the indirect harms caused by quarantine, lockdowns, repeat testing, school exclusion and closures, and other policies aimed at reducing community transmission, although the extent to which mass vaccination is necessary to achieve this remains unclear. Also, if the purpose of lockdowns and school closures is to protect adults, the incremental benefit of vaccinating children will be minimal once most adults are protected through vaccination. The possibility that vaccination might become a requirement for children for international travel is another consideration.

## Potential risks of vaccinating children

### Risk of adverse effects

As with any vaccine, there are potential rare adverse effects of COVID-19 vaccines. The development of myocarditis or pericarditis after mRNA vaccines has been a recent concern,<sup>91 92</sup> particularly in male adolescents (studies reporting 6.3–6.7 cases per 100 000 second vaccine doses in males aged 12–17 years,<sup>91 93</sup> and 15.1 cases per 100 000 second vaccine doses in males aged 16–19 years<sup>94</sup>). Another study reported an incidence of 10.7 cases per 100 000 persons in males aged 16–29 years.<sup>95</sup> Of these patients, approximately 6% required intensive care admission.<sup>96</sup> However, most recovered without sequelae (86% had resolution of symptoms after mean duration of 35 days).<sup>97 98</sup> Importantly, even in this age group, recent reports suggest the risk of myocarditis associated with COVID-19 is higher (see above).

The risk of thrombosis after viral vector vaccines observed rarely in adults also needs to be considered. The thrombotic risk in children or adolescents is less<sup>99</sup> and no cases have been reported to date in this age group. However, since the pathogenesis underlying thrombosis associated with COVID-19 vaccines is thought to differ from that for clots from other causes, such as stasis and the contraceptive pill, further data from children are necessary. As thrombotic events have either not been observed or appear to be very rare in Asia, Africa and Latin America, some countries are considering these vaccines as an option. The theoretical risk of COVID-19 vaccines triggering PIMS-TS has been raised but there are no reports of this to date.<sup>100</sup>

### Long-term safety

The lack of long-term safety data is another consideration. Longer term follow-up of myocarditis cases is needed to exclude any possibility of myocardial fibrosis and associated dysfunction or arrhythmia risk. Two studies showed a high prevalence of late gadolinium enhancement in MRIs in patients suffering from post-vaccine myocarditis.<sup>97 101</sup> Further studies are needed to establish whether this resolves or evolves into fibrosis. As discussed above, information on this risk is also needed for myocarditis resulting from SARS-CoV-2 infection.

Although the majority of adverse vaccine effects occur early after vaccination, any unforeseen adverse effects could undermine vaccine confidence and reduce vaccination rates against other diseases.<sup>102</sup>

### Vaccine supply

The currently limited global COVID-19 vaccine supply is another factor to consider. To date, many LMICs have only been able to vaccinate less than 5% of their population despite the COVAX programme. At this time, available supplies might be better prioritised for vaccinating adults with a higher risk of severe COVID-19 and death, including healthcare workers.<sup>103</sup> Another consideration is the higher immunogenicity of mRNA vaccines in children, meaning that one dose or a reduced dose might be sufficient to protect this age group.<sup>25</sup> On the other hand, the infrastructure to upscale the production of COVID-19 vaccines already exists and strategies for boosting global supply have been outlined.<sup>104</sup>

### Cost

Since the risks of intensive care admission or death in children are so low, the cost–benefit ratio of COVID-19 vaccination in children is higher. However, the emergence of new variants

might change this if these variants cause more frequent or more severe disease in children.<sup>105</sup> The cost of vaccination also needs to be balanced against the reduction in community transmission that might be achieved through vaccinating children, which would enable a faster return to pre-pandemic economic stability with associated benefits to children.

### Other immunisation programmes

Routine immunisation programmes for children and adolescents have been disrupted by the pandemic.<sup>106 107</sup> Implementing a universal COVID-19 vaccine programme for these age groups runs the risk of causing further delays by using up existing delivery resources and personnel. This in turn may harm children by resulting in more cases of vaccine-preventable infections and diseases such as cervical cancer, meningitis, measles and pertussis. However, if COVID-19 vaccination is combined with the administration of other routine vaccines, this problem might be reduced.

### CONCLUDING REMARKS

In summary, the case for vaccinating all healthy children against COVID-19 is more difficult than for adults as the balance of risks and benefits is more nuanced. If COVID-19 remains a generally mild disease in children and in vaccinated adults, it may not be necessary to vaccinate all children.<sup>90 108</sup> In addition, it is important to consider different age groups separately; the balance of risk and benefit of vaccination is likely to differ between infants, young children and adolescents. Children under 5 years of age are likely to need separate consideration to those 5–11 years of age. Continued monitoring of disease severity across all age groups is crucial. If a variant of concern emerges with increased severity in children (as is, for example, the case for Middle East respiratory syndrome-related coronavirus), this would alter the risk-benefit equation.<sup>90</sup> In LMICs, where the burden of COVID-19 is higher in the paediatric population as a result of comorbidities, there may be a lower threshold for vaccinating children. A one-dose schedule (as now recommended in the UK and Norway)<sup>109 110</sup> or a reduced-dose vaccine might be an option for this age group; this might also reduce the risk of myocarditis with the second dose of mRNA vaccines. Although mass COVID-19 vaccination of all ages, including children under 12 years of age, may become the general approach globally in the future, it seems wise at present to weigh up the risks and benefits with caution and to proceed with care.

**Twitter** Petra Zimmermann @Dr\_Petzi, Laure F Pittet @PittetLaure, Adam Finn @adamhfinn, Andrew J Pollard @ajpollard1 and Nigel Curtis @nigeltwitt

**Contributors** PZ drafted the initial manuscript. All authors critically revised the manuscript and approved the final manuscript as submitted.

**Funding** The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

**Disclaimer** The views expressed in this article do not necessarily represent the views of the DHSC, JCVI, NIHR or WHO.

**Competing interests** AJP is chair of UK Department of Health and Social Care's (DHSC) Joint Committee on Vaccination & Immunisation (JCVI), but does not participate in policy decisions on COVID-19 vaccine. He is a member of the WHO's SAGE. AJP is chief investigator on clinical trials of Oxford University's COVID-19 vaccine funded by NIHR. Oxford University has entered a joint COVID-19 vaccine development partnership with AstraZeneca. AF is an investigator in trials and studies of COVID-19 vaccines manufactured by Pfizer-BioNTech, AstraZeneca, Janssen, Valneva and Sanofi but receives no personal remuneration or benefits for this work. He is a member of the UK Joint Committee on Vaccination and Immunisation and chairs the WHO Euro Regional Technical Advisory Group of Experts (ETAGE) on immunisation.

**Patient consent for publication** Not required.

**Provenance and peer review** Not commissioned; externally peer reviewed.

**Data availability statement** No data are available. N/A.

This article is made freely available for personal use in accordance with BMJ's website terms and conditions for the duration of the covid-19 pandemic or until otherwise determined by BMJ. You may use, download and print the article for any lawful, non-commercial purpose (including text and data mining) provided that all copyright notices and trade marks are retained.

### ORCID iDs

Petra Zimmermann <http://orcid.org/0000-0002-2388-4318>  
 Laure F Pittet <http://orcid.org/0000-0002-2395-4574>  
 Adam Finn <http://orcid.org/0000-0003-1756-5668>  
 Andrew J Pollard <http://orcid.org/0000-0001-7361-719X>  
 Nigel Curtis <http://orcid.org/0000-0003-3446-4594>

### REFERENCES

- Göttinger F, Santiago-García B, Noguera-Julian A, et al. COVID-19 in children and adolescents in Europe: a multinational, multicentre cohort study. *Lancet Child Adolesc Health* 2020;4:653–61.
- Zimmermann P, Curtis N. Coronavirus infections in children including COVID-19: an overview of the epidemiology, clinical features, diagnosis, treatment and prevention options in children. *Pediatr Infect Dis J* 2020;39:355–68.
- Castagnoli R, Votto M, Licari A, et al. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in children and adolescents: a systematic review. *JAMA Pediatr* 2020;174:882–9.
- Ludvigsson JF. Systematic review of COVID-19 in children shows milder cases and a better prognosis than adults. *Acta Paediatr* 2020;109:1088–95.
- Zimmermann P, Curtis N. Why is COVID-19 less severe in children? A review of the proposed mechanisms underlying the age-related difference in severity of SARS-CoV-2 infections. *Arch Dis Child* 2021;106:429–39.
- Zimmermann P, Curtis N. COVID-19 in children, pregnancy and neonates: a review of epidemiologic and clinical features. *Pediatr Infect Dis J* 2020;39:469–77.
- Uka A, Buettcher M, Bernhard-Stirnermann S. Factors associated with hospital and intensive care admission in paediatric SARS-CoV-2 infection: a prospective nationwide observational cohort study. *Eur J Pediatr* 2021.
- Ward JL, Harwood R, Smith C. Risk factors for intensive care admission and death amongst children and young people admitted to hospital with COVID-19 and PIMS-TS in England during the first pandemic year. *medRxiv* 2021:2021.07.01.21259785.
- World Health Organization. COVID-19 detailed surveillance data dashboard. Available: <https://covid19.who.int> [Accessed 27 July 2021].
- Stokes EK, Zambrano LD, Anderson KN, et al. Coronavirus Disease 2019 Case Surveillance - United States, January 22-May 30, 2020. *MMWR Morb Mortal Wkly Rep* 2020;69:759–65.
- Verdoni L, Mazza A, Gervasoni A, et al. An outbreak of severe Kawasaki-like disease at the Italian epicentre of the SARS-CoV-2 epidemic: an observational cohort study. *Lancet* 2020;395:1771–8.
- Viner RM, Whittaker E. Kawasaki-like disease: emerging complication during the COVID-19 pandemic. *Lancet* 2020;395:1741–3.
- Moreira A. Kawasaki disease linked to COVID-19 in children. *Nat Rev Immunol* 2020;20:407.
- Toubiana J, Poirault C, Corsia A, et al. Kawasaki-like multisystem inflammatory syndrome in children during the covid-19 pandemic in Paris, France: prospective observational study. *BMJ* 2020;369:m2094.
- Riphagen S, Gomez X, Gonzalez-Martinez C, et al. Hyperinflammatory shock in children during COVID-19 pandemic. *Lancet* 2020;395:1607–8.
- Levin M. Childhood Multisystem Inflammatory Syndrome - A New Challenge in the Pandemic. *N Engl J Med* 2020;383:393–5.
- Moraleda C, Serna-Pascual M, Soriano-Arandes A. Multi-Inflammatory syndrome in children related to SARS-CoV-2 in Spain. *Clin Infect Dis* 2020;72:e397–401.
- Cheung EW, Zachariah P, Gorelik M, et al. Multisystem inflammatory syndrome related to COVID-19 in previously healthy children and adolescents in New York City. *JAMA* 2020;324:294–6.
- Whittaker E, Bamford A, Kenny J, et al. Clinical characteristics of 58 children with a pediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2. *JAMA* 2020;324:259–69.
- Payne AB, Gilani Z, Godfred-Cato S, et al. Incidence of multisystem inflammatory syndrome in children among US persons infected with SARS-CoV-2. *JAMA Netw Open* 2021;4:e2116420-e.
- Zimmermann P, Pittet LF, Curtis N. How common is long COVID in children and adolescents? *Pediatr Infect Dis J* 2021; Published Ahead of Print.
- European Medicines Agency. First COVID-19 vaccine Approved for children aged 12 to 15 in EU. Available: <https://www.ema.europa.eu/en/news/first-covid-19-vaccine-approved-children-aged-12-15-eu> [Accessed 24 Jul 2021].

- 23 National Institute for Health Research. Living with Covid-19. A dynamic review of the evidence around ongoing Covid-19 symptoms. Available: <https://evidence.nihr.ac.uk/themedreview/living-with-covid19/> [Accessed 24 Jul 2021].
- 24 National Advisory Committee on Immunization. Recommendations on the use of COVID-19 vaccines. Available: <https://www.canada.ca/en/public-health/services/immunization/national-advisory-committee-on-immunization-naci/recommendations-use-covid-19-vaccines.html> [Accessed 24 Jul 2021].
- 25 Frenc RW, Klein NP, Kitchin N, et al. Safety, immunogenicity, and efficacy of the BNT162b2 Covid-19 vaccine in adolescents. *N Engl J Med* 2021;385:239–50.
- 26 Ali K, Berman G, Zhou H, et al. Evaluation of mRNA-1273 SARS-CoV-2 vaccine in adolescents. *N Engl J Med* 2021. doi:10.1056/NEJMoa2109522. [Epub ahead of print: 11 Aug 2021].
- 27 Rose A, Stevo C, Alatovic J, et al. Pfizer and BioNTech announce positive topline results from pivotal trial of COVID-19 vaccine in children 5 to 11 years. Available: <https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-announce-positive-topline-results> [Accessed 4 Oct 2021].
- 28 Centers for Disease Control and Prevention. Demographic characteristics of people receiving COVID-19 vaccinations in the United States. Available: <https://covid.cdc.gov/covid-data-tracker/#vaccination-demographic> [Accessed 8 Oct 2021].
- 29 Lu X, Zhang L, Du H, et al. SARS-CoV-2 infection in children. *N Engl J Med* 2020;382:1663–5. doi:10.1056/NEJMc2005073
- 30 Bhuiyan MU, Stiboy E, Hassan MZ, et al. Epidemiology of COVID-19 infection in young children under five years: a systematic review and meta-analysis. *Vaccine* 2021;39:667–77.
- 31 Delahoy MJ, Ujamaa D, Whitaker M, et al. Hospitalizations Associated with COVID-19 Among Children and Adolescents - COVID-NET, 14 States, March 1, 2020–August 14, 2021. *MMWR Morb Mortal Wkly Rep* 2021;70:1255–60.
- 32 Siegel DA, Reses HE, Cool AJ, et al. Trends in COVID-19 Cases, Emergency Department Visits, and Hospital Admissions Among Children and Adolescents Aged 0–17 Years - United States, August 2020–August 2021. *MMWR Morb Mortal Wkly Rep* 2021;70:1249–54.
- 33 Havers FP, Whitaker M, Self JL, et al. Hospitalization of Adolescents Aged 12–17 Years with Laboratory-Confirmed COVID-19 - COVID-NET, 14 States, March 1, 2020–April 24, 2021. *MMWR Morb Mortal Wkly Rep* 2021;70:851–7.
- 34 Kim L, Whitaker M, O'Halloran A, et al. Hospitalization Rates and Characteristics of Children Aged <18 Years Hospitalized with Laboratory-Confirmed COVID-19 - COVID-NET, 14 States, March 1–July 25, 2020. *MMWR Morb Mortal Wkly Rep* 2020;69:1081–8.
- 35 Clare S, David O, Rachel H. Deaths in children and young people in England following SARS-CoV-2 infection during the first pandemic year: a national study using linked mandatory child death reporting data. *Research Square* 2021.
- 36 Singer ME, Taub IB, Kaelber DC. Risk of myocarditis from COVID-19 infection in people under age 20: a population-based analysis. *medRxiv* 2021:2021.07.23.21260998.
- 37 Boehmer TK, Kompaniyets L, Lavery AM, et al. Association Between COVID-19 and Myocarditis Using Hospital-Based Administrative Data - United States, March 2020–January 2021. *MMWR Morb Mortal Wkly Rep* 2021;70:1228–32.
- 38 Murk W, Gierada M, Fralick M, et al. Diagnosis-wide analysis of COVID-19 complications: an exposure-crossover study. *CMAJ* 2021;193:E10–18.
- 39 American Academy of Pediatrics. Children and COVID-19: State-Level data report 5 AUG 2021. Available: <https://services.aap.org/en/pages/2019-novel-coronavirus-covid-19-infections/children-and-covid-19-state-level-data-report/> [Accessed 11 Aug 2021].
- 40 Pegden W, Prasad V, Baral S. Covid vaccines for children should not get emergency use Authorization. The BMJ opinion, 2021. Available: <https://blogs.bmj.com/bmj/2021/05/07/covid-vaccines-for-children-should-not-get-emergency-use-authorization/>
- 41 Fernandes DM, Oliveira CR, Guerguis S, et al. Severe Acute Respiratory Syndrome Coronavirus 2 Clinical Syndromes and Predictors of Disease Severity in Hospitalized Children and Youth. *J Pediatr* 2021;230:e10:23–31.
- 42 Anderson EJ, Campbell JD, Creech CB, et al. Warp speed for coronavirus disease 2019 (COVID-19) vaccines: why are children stuck in neutral? *Clin Infect Dis* 2021;73:336–40.
- 43 Ogunyemi D, Mantilla R, Markus A, et al. Associations between structural and social determinants of health with COVID infection rates at a safety net Hospital. *Cureus* 2021;13:e17397.
- 44 Vahidy FS, Nicolas JC, Meeks JR, et al. Racial and ethnic disparities in SARS-CoV-2 pandemic: analysis of a COVID-19 observational Registry for a diverse us metropolitan population. *BMJ Open* 2020;10:e039849.
- 45 Penner J, Abdel-Mannan O, Grant K, et al. 6-Month multidisciplinary follow-up and outcomes of patients with paediatric inflammatory multisystem syndrome (PIMS-TS) at a UK tertiary paediatric Hospital: a retrospective cohort study. *Lancet Child Adolesc Health* 2021;5:473–82.
- 46 Davies P, Evans C, Kanthimathinathan HK, et al. Intensive care admissions of children with paediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 (PIMS-TS) in the UK: a multicentre observational study. *Lancet Child Adolesc Health* 2020;4:669–77.
- 47 Broad J, Forman J, Brighthouse J, et al. Post-COVID-19 paediatric inflammatory multisystem syndrome: association of ethnicity, key worker and socioeconomic status with risk and severity. *Arch Dis Child* 2021. doi:10.1136/archdischild-2020-320388. [Epub ahead of print: 16 Mar 2021].
- 48 Feldstein LR, Tenforde MW, Friedman KG, et al. Characteristics and outcomes of US children and adolescents with multisystem inflammatory syndrome in children (MIS-C) compared with severe acute COVID-19. *JAMA* 2021;325:1074–87.
- 49 Belay ED, Abrams J, Oster ME, et al. Trends in geographic and temporal distribution of US children with multisystem inflammatory syndrome during the COVID-19 pandemic. *JAMA Pediatr* 2021;175:837–45.
- 50 Flood J, Shingleton J, Bennett E, et al. Paediatric multisystem inflammatory syndrome temporally associated with SARS-CoV-2 (PIMS-TS): prospective, National surveillance, United Kingdom and Ireland, 2020. *Lancet Reg Health Eur* 2021;3:100075.
- 51 Riollano-Cruz M, Akkoyun E, Briceno-Brito E, et al. Multisystem inflammatory syndrome in children related to COVID-19: a New York City experience. *J Med Virol* 2021;93:424–33.
- 52 Minocha PK, Phoon CKL, Verma S, et al. Cardiac findings in pediatric patients with multisystem inflammatory syndrome in children associated with COVID-19. *Clin Pediatr* 2021;60:119–26.
- 53 Ramcharan T, Nolan O, Lai CY, et al. Paediatric inflammatory multisystem syndrome: temporally associated with SARS-CoV-2 (PIMS-TS): cardiac features, management and short-term outcomes at a UK tertiary paediatric Hospital. *Pediatr Cardiol* 2020;41:1391–401.
- 54 Osmanov IM, Spiridonova E, Bobkova P. Risk factors for long covid in previously hospitalised children using the ISARIC global follow-up protocol: a prospective cohort study. *Eur Respir J* 2021. [Epub ahead of print: 01 Jul 2021]. doi:10.1183/13993003.01341-2021
- 55 Miller F, Nguyen V, Navaratnam AMD. Prevalence of persistent symptoms in children during the COVID-19 pandemic: evidence from a household cohort study in England and Wales. *medRxiv* 2021.
- 56 Molteni E, Sudre CH, Canas LS, et al. Illness duration and symptom profile in symptomatic UK school-aged children tested for SARS-CoV-2. *Lancet Child Adolesc Health* 2021;5:708–18.
- 57 Buonsenso D, Munblit D, De Rose C, et al. Preliminary evidence on long COVID in children. *Acta Paediatr* 2021;110:2208–11.
- 58 Say D, Crawford N, McNab S, et al. Post-Acute COVID-19 outcomes in children with mild and asymptomatic disease. *Lancet Child Adolesc Health* 2021;5:e22–3.
- 59 Stephenson T, Shafran R, De Stavola B, et al. Long COVID and the mental and physical health of children and young people: national matched cohort study protocol (the clock study). *BMJ Open* 2021;11:e052838.
- 60 Sterky E, Olsson-Åkefeldt S, Hertting O, et al. Persistent symptoms in Swedish children after hospitalisation due to COVID-19. *Acta Paediatr* 2021;110:2578–80.
- 61 Radtke T, Ulyte A, Puhan MA, et al. Long-Term symptoms after SARS-CoV-2 infection in children and adolescents. *JAMA* 2021. doi:10.1001/jama.2021.11880. [Epub ahead of print: 15 Jul 2021].
- 62 Blomberg B, Mohn KG-L, Brokstad KA, et al. Long COVID in a prospective cohort of home-isolated patients. *Nat Med* 2021;27:1607–13.
- 63 Smane L, Stars I, Pucuka Z, et al. Persistent clinical features in paediatric patients after SARS-CoV-2 virological recovery: a retrospective population-based cohort study from a single centre in Latvia. *BMJ Paediatr Open* 2020;4:e000905.
- 64 Ayoubkhani D, Pawelek P, Gaughan C. Technical article: Updated estimates of the prevalence of post-acute symptoms among people with coronavirus (COVID-19) in the UK: 26 April 2020 to 1 August 2021. Available: <https://www.ons.gov.uk/people-leopulationandcommunity/healthandsocialcare/conditionsanddiseases/articles/technicalarticleupdatedestimatesoftheprevalenceofpostacuteysymptomsamongpeoplewithcoronaviruscovid19intheuk/26april2020to1august2021> [Accessed 4 Oct 2021].
- 65 Blankenburg J, Wekenborg MK, Reichert J. Mental health of adolescents in the pandemic: Long-COVID19 or Long-Pandemic syndrome? *medRxiv* 2021.
- 66 Buonsenso D, Espuny Pujol F, Munblit D. Clinical characteristics, activity levels and mental health problems in children with long COVID: a survey of 510 children. *Preprints* 2021.
- 67 Brackel CLH, Lap CR, Buddingh EP, et al. Pediatric long-COVID: an overlooked phenomenon? *Pediatr Pulmonol* 2021;56:2495–502.
- 68 Ashkenazi-Hoffnung L, Shmueli E, Ehrlich S. Long COVID in children: observations from a designated pediatric clinic. *Pediatr Infect Dis J* 2021; *Published Ahead of Print*.
- 69 Harris RJ, Hall JA, Zaidi A, et al. Effect of vaccination on household transmission of SARS-CoV-2 in England. *N Engl J Med* 2021;385:759–60.
- 70 Levine-Tiefenbrun M, Yelin I, Katz R. Decreased SARS-CoV-2 viral load following vaccination. *medRxiv* 2021.
- 71 Shah AS V, Gribben C, Bishop J. Effect of vaccination on transmission of COVID-19: an observational study in healthcare workers and their households. *medRxiv* 2021.
- 72 Riemersma KK, Grogan BE, Kita-Yarbro A. Shedding of infectious SARS-CoV-2 despite vaccination. *medRxiv* 2021.
- 73 Musser JM, Christensen PA, Olsen RJ. Delta variants of SARS-CoV-2 cause significantly increased vaccine breakthrough COVID-19 cases in Houston, Texas. *medRxiv* 2021.

- 74 Brown CM, Vostok J, Johnson H, *et al.* Outbreak of SARS-CoV-2 Infections, Including COVID-19 Vaccine Breakthrough Infections, Associated with Large Public Gatherings - Barnstable County, Massachusetts, July 2021. *MMWR Morb Mortal Wkly Rep* 2021;70:1059–62.
- 75 Chia PY, Xiang Ong SW, Chiew CJ. Virological and serological kinetics of SARS-CoV-2 delta variant vaccine-breakthrough infections: a multi-center cohort study. *medRxiv* 2021.
- 76 Chu VT, Yousaf AR, Chang K, *et al.* Household transmission of SARS-CoV-2 from children and adolescents. *N Engl J Med Overseas Ed* 2021;385:954–6.
- 77 Zhang J, Litvinova M, Liang Y, *et al.* Changes in contact patterns shape the dynamics of the COVID-19 outbreak in China. *Science* 2020;368:1481–6.
- 78 Ismail SA, Saliba V, Lopez Bernal J, *et al.* SARS-CoV-2 infection and transmission in educational settings: a prospective, cross-sectional analysis of infection clusters and outbreaks in England. *Lancet Infect Dis* 2021;21:344–53.
- 79 National Centre for Immunisation Research and Surveillance NCIRS. COVID-19 in schools – the experience in NSW. Available: <http://www.ncirs.org.au/covid-19-in-schools> [Accessed 16 Aug 2021].
- 80 National Institute for Public Health and the Environment, Netherlands. Children and COVID-19. Available: <https://www.rivm.nl/en/novel-coronavirus-covid-19/children-and-covid-19> [Accessed 16 Aug 2021].
- 81 Ladhani SN, Baawuah F, Beckmann J, *et al.* SARS-CoV-2 infection and transmission in primary schools in England in June–December, 2020 (SKIDS): an active, prospective surveillance study. *Lancet Child Adolesc Health* 2021;5:417–27.
- 82 Public Health England. Confirmed cases of COVID-19 variants identified in UK. Available: <https://www.gov.uk/government/news/confirmed-cases-of-covid-19-variants-identified-in-uk> [Accessed 10 Aug 2021].
- 83 Centers for Disease Control and Prevention. Delta variant: what we know about the science. Available: <https://www.cdc.gov/coronavirus/2019-ncov/variants/delta-variant.html> [Accessed 10 Aug 2021].
- 84 National Centre for Immunisation Research and Surveillance NCIRS. COVID-19 delta variant in schools and early childhood education and care services in NSW, Australia: 16 June to 31 July 2021. Available: [https://www.ncirs.org.au/sites/default/files/2021-09/NCIRS%20NSW%20Schools%20COVID\\_Summary\\_8%20September%2021\\_Final.pdf](https://www.ncirs.org.au/sites/default/files/2021-09/NCIRS%20NSW%20Schools%20COVID_Summary_8%20September%2021_Final.pdf) [Accessed 9 Sep 2021].
- 85 McLean HQ, Grijalva CG, Hanson KE, *et al.* Household transmission and clinical features of SARS-CoV-2 infections by age in 2 us communities. *medRxiv* 2021. doi:10.1101/2021.08.16.21262121. [Epub ahead of print: 20 Aug 2021].
- 86 Siebach MK, Piedimonte G, Ley SH. COVID-19 in childhood: transmission, clinical presentation, complications and risk factors. *Pediatr Pulmonol* 2021;56:1342–56.
- 87 Maltezou HC, Magaziotou I, Dedoukou X, *et al.* Children and adolescents with SARS-CoV-2 infection: epidemiology, clinical course and viral loads. *Pediatr Infect Dis J* 2020;39:e388–92.
- 88 Li F, Li Y-Y, Liu M-J, *et al.* Household transmission of SARS-CoV-2 and risk factors for susceptibility and infectivity in Wuhan: a retrospective observational study. *Lancet Infect Dis* 2021;21:617–28.
- 89 Paul LA, Daneman N, Schwartz KL, *et al.* Association of age and pediatric household transmission of SARS-CoV-2 infection. *JAMA Pediatr* 2021. doi:10.1001/jamapediatrics.2021.2770. [Epub ahead of print: 16 Aug 2021].
- 90 Lavine JS, Bjornstad ON, Antia R. Immunological characteristics govern the transition of COVID-19 to endemicity. *Science* 2021;371:741–5.
- 91 Gargano JW, Wallace M, Hadler SC, *et al.* Use of mRNA COVID-19 Vaccine After Reports of Myocarditis Among Vaccine Recipients: Update from the Advisory Committee on Immunization Practices - United States, June 2021. *MMWR Morb Mortal Wkly Rep* 2021;70:977–82.
- 92 Israelian Ministry of Health. Surveillance of myocarditis (inflammation of the heart muscle) cases between December 2020 and may 2021 (including). Available: <https://www.gov.il/en/departments/news/01062021-03> [Accessed 24 Jul 2021].
- 93 Bozkurt B, Kamat I, Hotez PJ. Myocarditis with COVID-19 mRNA vaccines. *Circulation* 2021;144:471–84.
- 94 Mevorach D, Anis E, Cedar N, *et al.* Myocarditis after BNT162b2 mRNA vaccine against Covid-19 in Israel. *N Engl J Med* 2021. doi:10.1056/NEJMoa2109730. [Epub ahead of print: 06 Oct 2021].
- 95 Witberg G, Barda N, Hoss S, *et al.* Myocarditis after Covid-19 vaccination in a large health care organization. *N Engl J Med* 2021. doi:10.1056/NEJMoa2110737. [Epub ahead of print: 06 Oct 2021].
- 96 Advisory Committee on Immunization Practices (ACIP), Centers for Disease Control and Prevention. COVID-19 vaccine safety updates. Available: <https://www.cdc.gov/vaccines/acip/meetings/slides-2021-06.html> [Accessed 27 Jul 2021].
- 97 Jain SS, Steele JM, Fonseca B, *et al.* COVID-19 Vaccination-Associated myocarditis in adolescents. *Pediatrics* 2021. doi:10.1542/peds.2021-053427. [Epub ahead of print: 13 Aug 2021].
- 98 Klein NP, Lewis N, Goddard K, *et al.* Surveillance for adverse events after COVID-19 mRNA vaccination. *JAMA* 2021;326:1390–1399.
- 99 Ignjatovic V, Mertyn E, Monagle P. The coagulation system in children: developmental and pathophysiological considerations. *Semin Thromb Hemost* 2011;37:723–9.
- 100 Blumenthal JA, Burns JP. Complexities of the COVID-19 vaccine and multisystem inflammatory syndrome in children. *Pediatr Investig* 2020;4:299–300.
- 101 Dionne A, Sperotto F, Chamberlain S, *et al.* Association of myocarditis with BNT162b2 messenger RNA COVID-19 vaccine in a case series of children. *JAMA Cardiol* 2021. doi:10.1001/jamacardio.2021.3471. [Epub ahead of print: 10 Aug 2021].
- 102 Re L V, 3Rd, Klungel OH, Chan ka, Panozzo Ca, Zhou W, Winterstein Ag. global covid-19 vaccine rollout and safety surveillance-how to keep PACE. *BMJ* 2021;373:n1416.
- 103 Our World in Data. COVID-19 vaccine doses administered. Available: <https://ourworldindata.org/grapher/cumulative-covid-vaccinations> [Accessed 24 Jul 2021].
- 104 Castillo JC, Ahuja A, Athey S, *et al.* Market design to accelerate COVID-19 vaccine supply. *Science* 2021;371:1107–9.
- 105 American Academy of Pediatrics. Available: <https://protect-au.mimecast.com/s/kTIQ Cp8AxKsn7BoR2HPuc2Q?domain=downloads.aap.org> [Accessed 10 Aug 2021].
- 106 Santoli JM, Lindley MC, DeSilva MB, *et al.* Effects of the COVID-19 Pandemic on Routine Pediatric Vaccine Ordering and Administration - United States, 2020. *MMWR Morb Mortal Wkly Rep* 2020;69:591–3.
- 107 Centers for Disease Control and Prevention, Messonnier N. Help kids' safe return to school - get caught up on recommended vaccines. Available: [www.cdc.gov/vaccines/hcp/clinical-resources/downloads/safe-return-school.pdf](http://www.cdc.gov/vaccines/hcp/clinical-resources/downloads/safe-return-school.pdf) [Accessed 16 Aug 2021].
- 108 Coleman PG, Perry BD, Woolhouse ME. Endemic stability--a veterinary idea applied to human public health. *Lancet* 2001;357:1284–6.
- 109 UK joint Committee on vaccination and immunisation. JCVI statement on COVID-19 vaccination of children aged 12 to 15 years: 3 September 2021. Available: <https://www.gov.uk/government/publications/jcvi-statement-september-2021-covid-19-vaccination-of-children-aged-12-to-15-years/jcvi-statement-on-covid-19-vaccination-of-children-aged-12-to-15-years-3-september-2021> [Accessed 4 Oct 2021].
- 110 Norwegian Institute of Public Health. 12-15-year-olds will be offered coronavirus vaccination. Available: <https://www.fhi.no/en/news/2021/12-15-year-olds-will-be-offered-coronavirus-vaccination/> [Accessed 4 Oct 2021].
- 111 Mizumoto K, Omori R, Nishiura H. Age specificity of cases and attack rate of novel coronavirus disease (COVID-19). *medRxiv* 2020.
- 112 Milani GP, Bottino I, Rocchi A, *et al.* Frequency of children vs adults carrying severe acute respiratory syndrome coronavirus 2 asymptomatically. *JAMA Pediatr* 2021;175:193–4.
- 113 Viner RM, Mytton OT, Bonell C, *et al.* Susceptibility to SARS-CoV-2 infection among children and adolescents compared with adults: a systematic review and meta-analysis. *JAMA Pediatr* 2021;175:143–156.
- 114 Jing Q-L, Liu M-J, Zhang Z-B, *et al.* Household secondary attack rate of COVID-19 and associated determinants in Guangzhou, China: a retrospective cohort study. *Lancet Infect Dis* 2020;20:1141–50.
- 115 Szablewski CM, Chang KT, Brown MM, *et al.* SARS-CoV-2 Transmission and Infection Among Attendees of an Overnight Camp - Georgia, June 2020. *MMWR Morb Mortal Wkly Rep* 2020;69:1023–5.
- 116 Viner R, Russell S, Saull R. Impacts of school closures on physical and mental health of children and young people: a systematic review. *medRxiv* 2021.
- 117 Medicines and Healthcare products Regulatory Agency. Coronavirus vaccine - weekly summary of Yellow Card reporting, 2021. Available: <https://www.gov.uk/government/publications/coronavirus-covid-19-vaccine-adverse-reactions/coronavirus-vaccine-summary-of-yellow-card-reporting>